Drugs / GNR-086
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06481189 | Sep 2022 → Mar 2023 | — | AO GENERIUM | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06497491 | Dec 2023 → May 2025 | adult-onset Still disease | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481189 ↗ |
| Route | Subcutaneous | “The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.” NCT06481189 ↗ |